13.1 Preconception Planning & Comprehensive Contraception Management

Preconception Optimization & Risk Mitigation

Preconception care represents one of the highest-yield preventive interventions in family medicine. The goal of preconception counseling is to identify, mitigate, and manage biomedical, behavioral, and environmental risks to a patient's health and pregnancy outcomes before conception occurs. Because approximately 45% of pregnancies in the United States remain unintended, and organogenesis begins during the third to eighth embryonic weeks—often before a patient recognizes pregnancy—preconception risk assessment must be integrated routinely into primary care encounters for all reproductive-capable individuals.

Folic Acid Supplementation Strategies

Neural tube closure occurs between 21 and 28 days post-conception. Neural tube defects (NTDs), including anencephaly and spina bifida (myelomeningocele), result from failure of embryonic neural tube fusion. Folic acid (pteroylglutamic acid) is essential for one-carbon metabolism and nucleotide synthesis during rapid cellular division.

• Standard-Risk Supplementation (USPSTF Grade A): All individuals planning or capable of pregnancy should consume 0.4 to 0.8 mg (400 to 800 mcg) of oral folic acid daily. Supplementation should ideally begin at least 1 month prior to conception and continue through at least the first 12 weeks (first trimester) of gestation, though continuing through delivery is standard prenatal practice.
• High-Risk Supplementation (4.0 mg [4,000 mcg] Daily): A ten-fold higher dose of 4.0 mg daily is indicated for high-risk clinical populations. High-dose supplementation must be initiated at least 1 to 3 months prior to conception and maintained through the first 12 weeks of gestation, after which it can be reduced to 0.4 to 0.8 mg daily. Specific high-risk criteria include:
  • Personal history of a prior pregnancy affected by a neural tube defect
  • Either prospective biological parent having a neural tube defect
  • Concurrent therapy with antiepileptic drugs that impair folate metabolism (specifically valproic acid and carbamazepine)
  • Pregestational diabetes mellitus (Type 1 or Type 2)
  • Malabsorption syndromes (active inflammatory bowel disease, celiac disease, prior bariatric bypass surgery)
  • Sickle cell disease and other chronic hemolytic anemias

---

Chronic Disease Optimization Prior to Conception

1. Pregestational Diabetes Mellitus (Type 1 & Type 2)

Hyperglycemia during organogenesis exerts direct teratogenic effects through reactive oxygen species generation, membrane lipid peroxidation, and cellular apoptosis in embryonic tissues. The risk of major congenital anomalies is directly proportional to periconceptional glycemic control:

• Glycemic Target: The preconception goal is an HbA1c <6.5% without frequent severe hypoglycemia. Every 1% reduction in HbA1c toward normal significantly decreases malformation rates.
• Associated Malformations: Uncontrolled periconceptional maternal hyperglycemia markedly elevates the risk of complex cardiac malformations (ventricular septal defects, transposition of the great arteries, coarctation of the aorta) and central nervous system defects. Most characteristically, it is associated with caudal regression syndrome (sacral agenesis)—an exceedingly rare malformation occurring 200 times more frequently in pregnancies complicated by uncontrolled pregestational diabetes.
• Long-Term Complication Screening: Assess for diabetic retinopathy (dilated funduscopic exam), nephropathy (serum creatinine, urine albumin-to-creatinine ratio), neuropathy, and cardiovascular disease before conception. Discontinue teratogenic non-insulin therapies (such as SGLT2 inhibitors and GLP-1 receptor agonists, for which human safety data remain limited) and transition to insulin as the gold standard for glycemic control in pregnancy.

2. Chronic Hypertension & Teratogenic Antihypertensive Transition

Chronic hypertension (blood pressure $\ge 130/80$ mm Hg prior to pregnancy or before 20 weeks gestation) increases the risk of superimposed preeclampsia, placental abruption, fetal growth restriction (FGR), and preterm delivery.

• Discontinuation of Teratogens: Inhibitors of the renin-angiotensin-aldosterone system (RAAS)—including ACE inhibitors (e.g., lisinopril), Angiotensin Receptor Blockers (ARBs, e.g., losartan), and direct renin inhibitors (aliskiren)—are potent fetotoxins. Exposure during the second and third trimesters causes fetal renal dysgenesis, profound oligohydramnios, pulmonary hypoplasia, skull ossification defects, limb contractures, and neonatal anuria. Mineralocorticoid receptor antagonists (spironolactone) exert anti-androgenic effects that disrupt male external genitalia development. All RAAS inhibitors and spironolactone must be discontinued prior to conception.
• First-Line Pregnancy-Safe Antihypertensives:
  1. Labetalol: Combined alpha-1 and non-selective beta-blocker. First-line oral dosing starts at 100 mg twice daily, titrating up to 800 mg twice or three times daily (maximum 2,400 mg/day). Avoid in patients with active reactive airway disease or severe bradycardia.
  2. Nifedipine (Extended-Release): Dihydropyridine calcium channel blocker. Starting dose 30 mg orally once daily, titrating up to 90–120 mg daily. Rapid-acting sublingual nifedipine is contraindicated due to precipitous hypotension and fetal hypoperfusion.
  3. Methyldopa: Central alpha-2 adrenergic agonist. Historic first-line agent with an extensive long-term pediatric safety track record, though limited by maternal somnolence, depression, and hepatic transaminitis. Dosing: 250 mg twice or three times daily up to 3,000 mg/day.
• Blood Pressure Goals: In accordance with the landmark CHAP trial, the recommended blood pressure target in chronic hypertension during pregnancy is systolic 110–135 mm Hg and diastolic 70–85 mm Hg to mitigate preeclampsia and maternal end-organ complications while preserving uteroplacental perfusion.

3. Teratogenic Medication Review & Discontinuation Timelines

---

Preconception Immunizations & Infectious Disease Screening

• Live Attenuated Vaccines (MMR and Varicella): Live vaccines pose a theoretical risk of viral transmission to the fetus and are strictly contraindicated during pregnancy. Clinicians must assess immunity (serologic titers or documented history) preconceptionally. If non-immune, administer the vaccine series and counsel the patient to avoid conception for at least 28 days (4 weeks) following vaccination.
• Inactivated Vaccines: Inactivated influenza vaccine (any trimester) and COVID-19 mRNA vaccines (any trimester) are strongly recommended to prevent severe maternal morbidity and respiratory failure.
• Tdap Vaccine: Administered during each pregnancy between 27 and 36 weeks of gestation (regardless of prior immunization status) to maximize transplacental passive transfer of maternal anti-pertussis antibodies to the neonate.
• Infectious Screening: Serologic screening for HIV, Syphilis (RPR/VDRL), Hepatitis B surface antigen (HBsAg), Rubella IgG, and Varicella IgG. Screen for Chlamydia trachomatis and Neisseria gonorrhoeae in all women $<25$ years of age and older individuals with clinical risk factors.

---

CDC US Medical Eligibility Criteria for Contraceptive Use (US MEC)

The Centers for Disease Control and Prevention (CDC) publishes the US Medical Eligibility Criteria for Contraceptive Use (US MEC), which provides evidence-based guidance on the safety of contraceptive methods in the presence of specific medical conditions. The US MEC categorizes safety into four distinct tiers:

The US MEC Numerical Classification System

• Category 1: A condition for which there is no restriction for the use of the contraceptive method. (Example: Levonorgestrel IUD in a patient with well-controlled hypertension).
• Category 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks. The method can be used with routine clinical follow-up. (Example: Combined oral contraceptives in an uncomplicated, controlled diabetic aged $<35$).
• Category 3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The method is NOT recommended unless other more appropriate methods are unavailable or unacceptable. (Example: Combined oral contraceptives in a woman aged $\ge 35$ who smokes $<15$ cigarettes/day).
• Category 4: A condition that represents an unacceptable health risk if the contraceptive method is used (absolute contraindication). (Example: Combined oral contraceptives in a patient with migraine with aura).

---

Contraceptive Efficacy Tiers & Method Characteristics

Contraceptive methods are grouped into three primary clinical tiers based on failure rates in typical real-world use:

                                  CONTRACEPTIVE EFFICACY TIERS
                                  
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │ TIER 1: Long-Acting Reversible Contraception (LARC) & Sterilization (<1% Failure Rate) │
  │ • Subdermal Etonogestrel Implant (Nexplanon: 0.05% failure rate, approved 3-5 years)   │
  │ • Levonorgestrel IUDs (52 mg Mirena/Liletta [8 yrs], 19.5 mg [5 yrs], 13.5 mg [3 yrs]) │
  │ • Copper T380A IUD (ParaGard: non-hormonal, 10-12 years, emergency contraception)      │
  │ • Female Tubal Occlusion / Male Vasectomy (permanent sterilization)                    │
  └───────────────────────────────────────────┬────────────────────────────────────────────┘
                                              │
  ┌───────────────────────────────────────────┴────────────────────────────────────────────┐
  │ TIER 2: Hormonal Injections, Pills, Patches & Rings (4–7% Typical Failure Rate)        │
  │ • Depot Medroxyprogesterone Acetate (DMPA: 150 mg IM / 104 mg SC q13wk, BMD warning)   │
  │ • Combined Oral Contraceptive Pills (COCs: daily, 21/7 or extended cycle)              │
  │ • Transdermal Patch (EE/Norelgestromin: weekly, VTE risk in BMI ≥30 kg/m²)             │
  │ • Vaginal Rings (NuvaRing: monthly; Annovera: reusable for 1 year)                     │
  │ • Progestin-Only Pills (POPs: Norethindrone strict 3h window; Drospirenone 24h window) │
  └───────────────────────────────────────────┬────────────────────────────────────────────┘
                                              │
  ┌───────────────────────────────────────────┴────────────────────────────────────────────┐
  │ TIER 3: Barrier, Behavioral & Coital Methods (13–24% Typical Failure Rate)             │
  │ • Male Condoms (13% typical failure, provides STI protection)                          │
  │ • Female Condoms, Diaphragms with Spermicide, Cervical Caps (17–21% failure)           │
  │ • Fertility Awareness-Based Methods, Withdrawal (Coitus Interruptus), Sponge (18–24%) │
  └────────────────────────────────────────────────────────────────────────────────────────┘

Tier 1: Long-Acting Reversible Contraceptives (LARC)

LARCs represent the most effective reversible methods because their efficacy is independent of patient adherence:

1. Subdermal Etonogestrel Implant (Nexplanon):

   • Design: Single 4-cm rod containing 68 mg of etonogestrel placed subdermally in the non-dominant inner upper arm. Approved for 3 years, with clinical trial evidence demonstrating efficacy through 5 years.
   • Mechanism: Ovulation suppression via pituitary LH inhibition, thickening of cervical mucus, and endometrial thinning. Highest efficacy of any reversible contraceptive ($<0.05%$ failure rate).
   • Clinical Side Effects & Counseling: Unscheduled, irregular, unpredictable uterine bleeding is the most common adverse effect and the leading reason for premature discontinuation. Amenorrhea develops in approximately 20% of users. Bleeding episodes can be managed with a 5- to 7-day course of oral NSAIDs (e.g., ibuprofen 600–800 mg three times daily), a 1- to 3-month trial of combined oral contraceptives, or oral tranexamic acid.

2. Levonorgestrel Intrauterine Devices (LNG-IUD):

   • 52 mg Formulations (Mirena, Liletta): Initial release ~20 mcg/day; approved for up to 8 years. Causes marked local endometrial decidualization and glandular atrophy, while thickening cervical mucus. Significantly reduces menstrual blood loss (by up to 90%) and dysmenorrhea; amenorrhea occurs in 20% of patients at 1 year and 50% at 5 years. First-line therapy for idiopathic heavy menstrual bleeding (menorrhagia).
   • 19.5 mg (Kyleena): Approved for 5 years; intermediate hormone dose and smaller frame.
   • 13.5 mg (Skyla): Approved for 3 years; lowest hormone dose and smaller frame, tailored for nulliparous patients with smaller uterine cavities.

3. Copper T380A Intrauterine Device (ParaGard):

   • Design: Completely non-hormonal, polyethylene T-frame wrapped with 380 mm² of copper wire. FDA-approved for 10 years, with high efficacy demonstrated through 12 years.
   • Mechanism: Continuous release of copper ions creates a sterile, cytotoxic foreign body inflammatory reaction in the endometrium and uterine fluid, which is toxic to spermatozoa and oocytes, preventing fertilization.
   • Clinical Side Effects: Frequently increases menstrual volume and crampy dysmenorrhea, particularly during the first 3 to 6 cycles. Managed with pre-emptive scheduled NSAIDs during menses. Highly preferred in patients who have contraindications to exogenous hormones or desire non-hormonal contraception.

---

Tier 2: Short-Acting Hormonal Contraceptives

1. Combined Hormonal Contraceptives (CHCs: Pills, Patch, Ring):

   • Mechanism: Ethinyl estradiol (EE) suppresses FSH secretion (inhibiting follicular recruitment), while the progestin component suppresses the mid-cycle LH surge (inhibiting ovulation) and thickens cervical mucus.
   • Transdermal Patch (Xulane, Twirla): Applied once weekly for 3 consecutive weeks, followed by 1 patch-free week. Generates higher steady-state systemic estrogen concentrations than standard 30-mcg COCs. Efficacy is significantly decreased and the risk of venous thromboembolism is increased in individuals with a BMI $\ge 30$ kg/m² or body weight $\ge 90$ kg.
   • Vaginal Rings: NuvaRing (etonogestrel/EE: worn intravaginally for 3 weeks, removed for 1 week); Annovera (segesterone acetate/EE: reusable ring washed and reinserted monthly for 1 full year).

2. Progestin-Only Pills (POPs):

   • Norethindrone (0.35 mg, "Mini-Pill"): Does NOT reliably suppress ovulation (ovulation is inhibited in only ~50% of cycles); works primarily by thickening cervical mucus and thinning the endometrium. Due to a short plasma half-life, the cervical mucus effect wanes after 22 hours. Must be taken at the exact same time every day within a strict 3-hour window. If a pill is missed by $>3$ hours, the patient must take the missed pill immediately, continue daily dosing, and use backup barrier contraception for at least 48 hours.
   • Drospirenone (4 mg, Slynd): 24 active pills and 4 inert pills. Reliably suppresses ovulation. Features a 24-hour missed-pill window, offering superior forgiving pharmacokinetics compared to norethindrone. Drospirenone is a spironolactone analogue with mild anti-mineralocorticoid activity; serum potassium monitoring is necessary only in patients with renal impairment, hepatic dysfunction, or concurrent potassium-sparing medication use.

3. Depot Medroxyprogesterone Acetate (DMPA, Depo-Provera):

   • Dosing: 150 mg intramuscularly or 104 mg subcutaneously every 13 weeks (grace period up to 15 weeks without requiring exclusion of pregnancy).
   • Mechanism: High-dose progestin reliably blocks pituitary gonadotropin secretion, suppressing follicular maturation and ovulation.
   • Clinical Adverse Effects & Boxed Warnings:
     • Bone Mineral Density (BMD) Loss: Carries an FDA boxed warning regarding reversible reduction in bone mineral density. Bone loss stabilizes over time, and BMD substantially recovers following discontinuation. Routine surveillance with DEXA scans is NOT recommended by ACOG or the CDC, and therapy should not be arbitrarily restricted to 2 years if other methods are unsuitable.
     • Delayed Return to Fertility: Following cessation of DMPA, return to regular ovulatory cycles is delayed, averaging 9 to 18 months (median 10 months). DMPA is not ideal for patients desiring pregnancy within the subsequent 1 to 2 years.
     • Weight Gain: Average weight gain of 2 to 5 kg over 1 to 2 years, primarily in adolescents and overweight individuals.
     • Amenorrhea: Progressive amenorrhea develops in 50% of users by 1 year and 70% by 2 years.

---

Absolute Contraindications to Estrogen-Containing Contraceptives (US MEC 4)

Because ethinyl estradiol enhances hepatic synthesis of coagulation factors (factors II, VII, VIII, X, and fibrinogen) and decreases antithrombin III, combined hormonal contraceptives (COCs, patch, ring) increase the risk of venous thromboembolism and arterial thrombosis. Estrogen-containing contraceptives are strictly US MEC Category 4 (Unacceptable Health Risk) in the following clinical scenarios:

Master US MEC Category 4 Matrix for Combined Hormonal Contraceptives

Exam Distinction: Migraine without aura in patients $<35$ years is US MEC Category 2 (advantages outweigh risks). Migraine without aura in patients $\ge 35$ years is US MEC Category 3 for continuation and Category 3/4 for initiation.

---

Emergency Contraception (EC): Protocols & Clinical Pharmacology

Emergency contraception provides an opportunity to prevent unintended pregnancy following unprotected intercourse, sexual assault, or contraceptive failure (e.g., condom rupture, missed oral pills). There are three primary emergency contraception modalities:

                                    EMERGENCY CONTRACEPTION MODALITIES
                                    
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │ 1. COPPER T380A IUD (ParaGard)                                                         │
  │ • Timing: Insert within 120 hours (5 days) of unprotected coitus                       │
  │ • Efficacy: >99.9% effective (<0.1% failure rate) — Gold Standard                      │
  │ • BMI Impact: Unaffected by overweight or obesity (equally effective across all BMIs)   │
  │ • Mechanism: Direct spermicidal and ovicidal inflammatory endometrial effect           │
  │ • Benefit: Provides immediate, ongoing Tier 1 contraception for 10–12 years            │
  └────────────────────────────────────────────────────────────────────────────────────────┘
                                              │
             ┌────────────────────────────────┴────────────────────────────────┐
             ▼                                                                 ▼
┌─────────────────────────────────────────┐       ┌─────────────────────────────────────────┐
│ 2. ORAL ULIPRISTAL ACETATE (Ella, 30mg) │       │ 3. ORAL LEVONORGESTREL (Plan B, 1.5mg)  │
│ • Window: Within 120 hours (5 days)     │       │ • Window: Within 72 hours (up to 120h)  │
│ • Type: Progesterone receptor modulator │       │ • Type: High-dose progestin             │
│ • Efficacy: Superior to LNG across 5 d  │       │ • Efficacy: ~85–90% (declines over time)│
│ • BMI: Effective in BMI ≥30 kg/m²       │       │ • BMI: Diminished in BMI ≥25–30 kg/m²   │
│ • Crucial Rule: PAUSE routine hormonal  │       │ • Quick Start: Start/resume routine     │
│   contraception for 5 full days; barrier│       │   hormonal contraception IMMEDIATELY    │
│   backup for 14 days or until menses    │       │   on same day; barrier backup for 7 d   │
│ • Requires prescription                 │       │ • Available over-the-counter (no ID/age)│
└─────────────────────────────────────────┘       └─────────────────────────────────────────┘

Clinical Pharmacology & Protocol Nuances

1. Copper T380A IUD

• Efficacy: Greater than $99.9%$ efficacy when inserted within 120 hours (5 days) of unprotected intercourse. Represents the single most effective emergency contraceptive method.
• Recent Guideline Update: Clinical trials have established that the 52-mg Levonorgestrel IUD (Mirena/Liletta) is non-inferior to the copper IUD when inserted within 5 days for emergency contraception, expanding patient choice for emergency LARC placement.

2. Oral Ulipristal Acetate (Ella, 30 mg)

• Pharmacology: Selective progesterone receptor modulator (SPRM). It prevents or delays follicular rupture and ovulation.
• Ovulatory Window Advantage: Unlike levonorgestrel, ulipristal acetate maintains the ability to inhibit ovulation even after the luteinizing hormone (LH) surge has already started, up until the immediate pre-ovulatory LH peak. Consequently, it demonstrates superior efficacy compared to levonorgestrel throughout the entire 120-hour (5-day) window.
• Weight / BMI Performance: Ulipristal acetate retains high efficacy in patients who are overweight or obese (BMI $\ge 30$ kg/m²), whereas levonorgestrel efficacy declines markedly.
• THE DRUG INTERACTION EXAM PEARL (The 5-Day Rule): Because ulipristal binds competitively to progesterone receptors, administering exogenous progestins (such as initiating combined oral contraceptives, POPs, DMPA, or implants) immediately after ulipristal blunts ulipristal's emergency contraceptive efficacy and reduces the efficacy of the progestin. Therefore, patients who take ulipristal must WAIT at least 5 days before starting or restarting any hormonal contraceptive method. Furthermore, the patient must use a barrier method (condoms) for the 5-day waiting period PLUS an additional 7 to 14 days (total of 14 days or until their next menstrual period).

3. Oral Levonorgestrel (Plan B One-Step, 1.5 mg)

• Pharmacology: Single 1.5 mg dose of high-dose levonorgestrel (or two 0.75 mg doses 12 hours apart). Acts strictly by blunting the LH surge before the LH rise has begun. If the LH surge is already underway or ovulation has occurred, levonorgestrel has zero clinical efficacy.
• Timing: Labeled for administration within 72 hours (3 days) of unprotected intercourse, though it exhibits modest efficacy up to 120 hours (with progressive day-over-day efficacy decline).
• Weight / BMI Limitations: Levonorgestrel demonstrates significantly reduced efficacy in women with a BMI $\ge 25$ kg/m² and is considered largely ineffective in individuals with a BMI $\ge 30$ kg/m². In overweight and obese patients, the copper IUD or ulipristal acetate is strongly preferred.
• Same-Day Quick Start: Routine hormonal contraceptives can be started or resumed immediately on the same day following levonorgestrel intake. The patient must use barrier contraception for the subsequent 7 days.
• Access: Available over-the-counter (OTC) to individuals of all genders and ages without a prescription, parental consent, or age verification.